Cytokine polymorphisms and histologic expression in autopsy studies: contribution of TNF-alpha and TGF-beta 1 to the pathogenesis of autoimmune-associated congenital heart block.
Although Abs to SSA/Ro-SSB/La are necessary for the development of congenital heart block (CHB), the low frequency suggests that fetal factors are contributory. Because CHB involves a cascade from inflammation to scarring, polymorphisms of the TNF-alpha promoter region and codons 10 and 25 of the TGF-beta gene were evaluated in 88 children (40 CHB, 17 rash, 31 unaffected siblings) and 74 mothers from the Research Registry for Neonatal Lupus (NL). Cytokine expression was assessed in autopsy material from two fetuses with CHB. Significantly increased frequency of the -308A (high-producer) allele of TNF-alpha was observed in all NL groups compared with controls. In contrast, the TGF-beta polymorphism Leu(10) (associated with increased fibrosis) was significantly higher in CHB children (genotypic frequency 60%, allelic frequency 78%) than unaffected offspring (genotypic frequency 29%, p = 0.016; allelic frequency 56%, p = 0.011) and controls, while there were no significant differences between controls and other NL groups. For the TGF-beta polymorphism, Arg(25), there were no significant differences between NL groups and controls. In fetal CHB hearts, protein expression of TGF-beta, but not TNF-alpha, was demonstrated in septal regions, extracellularly in the fibrous matrix, and intracellularly in macrophage infiltrates. Age-matched fetal hearts from voluntary terminations expressed neither cytokine. TNF-alpha may be one of several factors that amplify susceptibility; however, the genetic studies, backed by the histological data, more convincingly link TGF-beta to the pathogenesis of CHB. This profibrosing cytokine and its secretion/activation circuitry may provide a novel direction for evaluating fetal factors in the development of a robust animal model of CHB as well as therapeutic strategies in humans.
Clancy
Robert M
RM
Hospital for Joint Diseases, New York University School of Medicine, Department of Rheumatology, New York, NY 10003, USA.
Backer
Chelsea B
CB
Yin
Xiaoming
X
Kapur
Raj P
RP
Molad
Yair
Y
Buyon
Jill P
JP
D001120:Arginine / Q000235:genetics; D001327:Autoimmune Diseases / Q000151:congenital / Q000235:genetics* / Q000473:pathology; D001344:Autopsy; D002648:Child; D016207:Cytokines / Q000096:biosynthesis* / Q000235:genetics*; D005076:Exanthema / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D005260:Female; D005315:Fetal Diseases / Q000235:genetics / Q000473:pathology; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D006327:Heart Block / Q000151:congenital / Q000235:genetics* / Q000276:immunology / Q000473:pathology; D006801:Humans; D007930:Leucine / Q000235:genetics; D009035:Mothers; D011110:Polymorphism, Genetic / Q000276:immunology*; D012333:RNA, Messenger / Q000096:biosynthesis; D016212:Transforming Growth Factor beta / Q000235:genetics / Q000502:physiology*; D053773:Transforming Growth Factor beta1; D014409:Tumor Necrosis Factor-alpha / Q000502:physiology*
D016207:Cytokines; D012333:RNA, Messenger; C508960:TGFB1 protein, human; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; D014409:Tumor Necrosis Factor-alpha; D001120:Arginine; D007930:Leucine